ImmunoGen won accelerated FDA approval for ... but there are many other examples, including MSD’s recent decision to license three ADCs from Daiichi Sankyo for $4 billion upfront and a total ...
ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback